MEN1 and pancreatic neuroendocrine tumor: By comparing the clinical features of probands with NETs with and without variants in MEN1, pancreatic NET was overrepresented in MEN1 positive patients (4/4, 100%) but recurred also in MEN1 negative cases (12/18, 66.7%) (p > 0.05) (Table 4).